Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFlorida Blue Medical/Specialty Pharmacy Prior Auth…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentFlorida BluePolicy N/A

    Medical/Specialty Pharmacy (Rx) Drug Prior Authorization Requirements

    Customize your policy alerts

    Sign up for all Florida Blue policy alerts

    Know when Florida Blue releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Florida Blue requirements and submission routing for prior authorization of Medical/Specialty Pharmacy drugs billed through the medical benefit and lists drugs/HCPCS that require prior authorization for applicable products and settings.

    Policy Summary
    PayerFlorida Blue
    PolicyMedical/Specialty Pharmacy (Rx) Drug Prior Authorization Requirements
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization referencing the listed drug, member product type and place of service before billing to avoid claim denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    20+drug entries shown in this excerpt
    multipleitems with PADP flag
    severalfuture management changes noted
    C9399common billing prefix

    Coverage & Authorization Conditions

    General coverage conditions tied to prior authorization

    Covered when prior authorization is obtained and the member's product covers the drug per medical necessity.

    Prior authorization precondition: Service is billed to a product and setting that requires prior authorization as listed (e.g., BlueCare HMO, My Blue, Medicare Advantage HMO/PPO, BlueSelect, BlueOptions, BlueChoice Group, SimplyBlue Group, Truli).

    Failure to obtain required prior authorization may result in denial and member/provider financial liability. See product list in source.

    Medical necessity: All services must meet the definition of medical necessity in the member's benefit contract.

    Medical necessity may be verified pre-service, concurrently, or post-service depending on product.

    Prior Authorization - List Inclusion

    Drugs listed require prior authorization as indicated by inclusion on the Medical/Specialty Pharmacy (Rx) Drug List.

    List inclusion: The requested drug or drug service is included on the Medical/Specialty Pharmacy (Rx) Drug List excerpt.

    Inclusion on the list implies a prior authorization requirement (PADP/CE/SAD flags shown per entry). No additional per‑drug clinical criteria are provided in this excerpt.

    Prior Authorization — general

    Listed drugs require prior authorization; specific coverage criteria are maintained elsewhere in the policy.

    Prior authorization required: Prior authorization is required for drugs listed in this specialty/medical pharmacy drug list segment (including entries under unclassified HCPCS like J3490/J3590 where applicable).

    This document segment is a PA drug list; specific clinical medical-necessity criteria for each drug are not present in the excerpt and must be referenced in the drug-specific policy or benefit documents.

    Prior Authorization Requirement

    Drugs listed require prior authorization.

    PA requirement: Prior authorization must be obtained for administration/claim of the drugs listed by J-code in this section (e.g., intra-articular hyaluronan products J7321–J7331 entries shown).

    Specific clinical criteria per drug are not included in these chunks; providers must submit PA requests referencing the listed J-code, drug name, and any PADP/CE flags shown.

    The Medical/Specialty Pharmacy (Rx) Drug List is a tool to identify drugs and associated HCPCS/CPT codes that may require prior authorization, but inclusion on the list alone does not guarantee coverage. Verify the member's eligibility and benefits before providing services—coverage is determined by the member's benefit contract and product. The list also does not show prior authorization requirements for medications processed and covered through the member's Pharmacy Benefit Manager (PBM), and it should not be used for BlueCard out-of-area members.

    Varithena (polidocanol injectable foam) is listed with a comment that the drug is not separately allowed and is “bundled within”. When Varithena appears under an unclassified listing (C9399) or J-code entry with this comment, it indicates the product is not separately reimbursable and is paid as part of another bundled service rather than as a discrete drug line item.

    Some list entries (for example Varithena under J3490) include the note “Drug not separately allowed, bundled within.” This wording signals that the drug is not separately reimbursed when billed in combination with the primary procedure or service and should not be billed as a separately payable pharmaceutical in those instances.

    Coverage and prior authorization requirements vary by member plan and product. The drug list is informational for PA processing, but benefits must be verified with Eligibility & Benefits (E&B) prior to service because listed drugs may not be covered under every member's medical benefit.

    HCPCS / J-Code / CPT Listings

    List entry code prefixmixed
    J90xxOncology and biologic injectables group (sample prefix)
    C90xxCellular/product codes prefix
    Referenced HCPCSHCPCS
    J0129ABATACEPT (ORENCIA)
    J0139ADALIMUMAB (HUMIRA)
    Listed HCPCS / C-codes and J-codes (partial)HCPCSCovered
    C9047CABLIVI (CAPLACIZUMAB-YHDP)
    C9174DATROWAY (DATOPOTAMAB DERUXTECAN-DLNK)
    A9513LUTATHERA (LUTETIUM LU 177)
    Additional J-codes (partial)HCPCSCovered
    J0118Sample referenced code
    J-code drug group (partial)HCPCSCovered
    J0775XIAFLEX (COLLAGENASE)
    J0791ADAKVEO (CRIZANLIZUMAB)
    J0799YEZTUGO (LENACAPAVIR)
    Additional J-code group (partial)HCPCSCovered
    J0801HP ACTHAR (CORTICOTROPIN)
    J0870RYTELO (IRNETELSTAT)
    Listed J-codes (partial)HCPCSCovered
    J0881ARANESP (DARBEPOETIN ALFA)
    J0885EPOGEN / PROCRIT (EPOETIN ALFA)
    J0887MIRCERA (EPOETIN BETA)
    Listed J-codes (continued)HCPCSCovered
    J0901VAFSEO (VADADUSTAT)
    J1071DEPO-TESTOSTERONE
    Further J-codesHCPCSCovered
    J1201QUZYTTIR (CETIRIZINE HYDROCHLORIDE)
    J1299SOLIRIS (ECULIZUMAB)
    J1306LEQVIO (INCLISIRAN)
    J-codes (continued)HCPCSCovered
    J1323ELREXFIO / EPOPROSTENOL
    J1411HEMGENIX
    Gene therapy and ASO J-codesHCPCSCovered
    J1412ROCTAVIAN
    J1413ELEVIDYS
    J1414BEQVEZ
    Additional J-codesHCPCSCovered
    J1426AMONDYS 45
    J1428EXONDYS 51
    Additional J-codesHCPCSCovered
    J1434FOCINVEZ (FOSAPREPITANT)
    J1437MONOFERRIC
    J1440REBYOTA
    Growth factor and other J-codesHCPCSCovered
    J1442NEUPOGEN (FILGRASTIM)
    J1447GRANIX (TBO-FILGRASTIM)
    J1449ROLVEDON (EFLAPEGRASTIM)
    Immune globulin J-codesHCPCSCovered
    J1551CUTAQUIG
    J1554ASCENIV
    J1555CUVITRU
    Additional IVIG/Subcutaneous productsHCPCSCovered
    J1556Human Immune Globulin (misc)
    J1557GAMMAPLEX
    J1558XEMBIFY
    Miscellaneous J-codesHCPCSCovered
    J1566Multiple immune globulin products (CARIMUNE NF, GAMMAGARD SD, etc.)
    J1569GAMMAGARD LIQUID
    J1575HYQVIA
    Anticoagulant and other J-codesHCPCSCovered
    J1645FRAGMIN (DALTEPARIN)
    J1650LOVENOX (ENOXAPARIN)
    J1652ARIXTRA (FONDAPARINUX)
    Covered J-Codes (partial list)HCPCSCovered
    J2490Sample placeholder
    Additional Covered J-Codes (partial)HCPCSCovered
    J3032VYEPTI (EPTINEZUMAB)
    J3055TALVEY (TALQUETAMAB)
    HCPCS / J-code group (continued)HCPCSCovered
    J3590Unclassified biologics / multiple entries (see list)
    J7173ALHEMO (CONCIZUMAB)
    J7174QFITLIA (FITUSIRAN)
    Listed HCPCS / Unclassified codes shownHCPCS
    J9999Unclassified / various (see list)
    J3490Unclassified drug codes (many entries)
    Unclassified/various (J3590 entries)HCPCS
    J3590Unclassified biologic entries (e.g., ACTEMRA SQ, ADALIMUMAB-AACF, etc.)
    Covered HCPCS/J codes listed in this windowHCPCSCovered
    J3358STELARA IV
    J3380ENTYVIO
    J-code Drug List (selected)HCPCSCovered
    J9118ASPARLAS (CALASPARGASE PAGOL)
    J9119LIBTAYO (CEMIPLIMAB)
    J9144DARZALEX FASPRO (DARATUMUMAB & HYALURONIDASE)
    J9145DARZALEX (DARATUMUMAB)
    J9153VYXEOS (DAUNORUBICIN and CYTARABINE)
    J9155FIRMAGON (DEGARELIX)
    J9171DOCEFREZ / TAXOTERE (DOCETAXEL)
    J9172DOCETAXEL
    J9173IMFINZI (DURVALUMAB)
    J9174BEIZRAY (DOCETAXEL)
    1–10 of 18
    1/2
    Additional J-codesHCPCSCovered
    J9024TECENTRIQ HYBREZA (ATEZOLIZUMAB & HYALURONIDASE)
    J9025VIDAZA (AZACITIDINE)
    J9026IMDELLTRA (TARLATAMAB-DLLE)
    J9028ANKTIVA
    J9029ADSTILADRIN
    J9036BELRAPZO
    J9038NIKTIMVO
    J9039BLINCYTO
    J9041VELCADE
    J9043JEVTANA
    1–10 of 24
    1/3
    Listed HCPCS/J-codes in this document partHCPCSCovered
    J9300Sample placeholder
    Covered HCPCS/J-codes listed (partial)HCPCSCovered
    J9355HERCEPTIN (TRASTUZUMAB)
    J9356HERCEPTIN HYLECTA
    J9358ENHERTU
    Covered HCPCS/J-codes continuedHCPCSCovered
    J9361RYZNEUTA
    J9376VEOPOZ
    Unclassified HCPCS J9999 entriesHCPCS
    J9999Various unclassified entries (see list)
    Covered Q- and supplemental HCPCS codes (biosimilars and biologics)HCPCSCovered
    Q2041YESCARTA (AXICABTAGENE CILOLEUCEL)
    Q2042KYMRIAH (TISAGENLECLEUCEL)
    Q2043PROVENGE
    Additional Q-codesHCPCSCovered
    Q2053TECARTUS
    Prior Authorization Drug Entries (coding table)HCPCSCovered
    J9024TECENTRIQ HYBREZA (ATEZOLIZUMAB & HYALURONIDASE)
    J9025VIDAZA (AZACITIDINE)
    J9026IMDELLTRA (TARLATAMAB-DLLE)
    J9028ANKTIVA (NOGAPENDEKIN ALFA INBAKICEPT)
    J9029ADSTILADRIN (NADOFARAGENE FIRADENOVEC)
    J9036BELRAPZO (BENDAMUSTINE HCI)
    J9038NIKTIMVO (AXATILIMAB)
    J9039BLINCYTO (BLINATUMOMAB)
    J9041VELCADE (BORTEZOMIB)
    J9043JEVTANA (CABAZITAXEL)
    1–10 of 42
    1/5

    What Providers Must Do

    Prior Authorization

    Prior Authorization Required

    Florida Blue requires prior authorization (PA) for Medical/Specialty Pharmacy drugs and related services when the member’s product or utilization management program specifies PA is required. Claims for listed drugs (including J-/HCPCS, C9399, and unclassified codes) submitted without the required prior authorization may be denied or require manual review; administration/supportive service codes are considered supportive when the drug itself requires PA unless otherwise specified.

    • Prior authorization required for drugs listed in the Medical/Specialty Pharmacy Drug List (includes J-codes, HCPCS, C9399 entries and unclassified Rx entries).
    • PADP-marked drugs (PADP = x) are managed by Prime Therapeutics Management (Prime MPS) and require submission to Prime per routing guidance.
    • Some HCPCS/J-codes are noted as new effective dates (e.g., J3389, J3387, J0013, J1073, J7174, J3402, J9184, J9184, J9184) — verify code changes when preparing requests.
    • Failure to obtain PA prior to service may result in denial and financial liability per the member’s contract.
    Note

    Where to Submit Prior Authorization

    Determine the correct Florida Blue or vendor destination before submitting PA requests. Review these items to identify where to submit: specific drug (brand/generic), member product type (e.g., BlueCare HMO, Medicare Advantage, etc.), place of service, rendering entity participation status, and the entity billing the drug.

    • Required identification elements: Specific Drug; Member Product Type; Place of Service; Rendering Entity Participation Status; Rendering Entity (Entity Billing Drug).
    • Products that commonly require PA are listed (examples: BlueCare HMO, My Blue, Medicare Advantage HMO/PPO, BlueSelect, BlueOptions, BlueChoice, SimplyBlue, Truli). Verify eligibility/benefit prior to services.
    Note

    Where to Submit — Vendor Routing Examples

    Where to submit — routing summary (consolidated): vendor/phone/fax/portal depend on product, PADP status, and whether the provider is CareCentrix-participating. Use the vendor portal or phone/fax indicated below.

    • Prime Therapeutics Management (Prime MPS / formerly MRxM/ICORE) provider self-service: https://gatewaypa.com/ (Physician tab) or phone (800) 424-4947 — used for All** PADP drugs not serviced by a CareCentrix contracted provider.
    • Submit electronically through Availity or contact Florida Blue via Blue Express (automated phone) for All drugs not included in PADP and not serviced by CareCentrix.
    • CareCentrix (CCX) coordinates reviews for Home Health, Home Infusion, or AIS participating providers — Phone (877) 561-9910, Fax (877) 627-6688.
    • Prime Therapeutics LLC (PBM) phone/fax listed for Part D/MedAdv and certain U65 plans per the PA routing guidance.
    Documentation Required

    Required Fields and Documentation

    Required fields and documentation on a PA request: include drug name (and generic/alternate name), applicable PADP/CE/SAD flags, drug/service date, HCPCS/J-code(s) or unclassified code (C9399/J3490/J3590 etc.), and clear comments supporting the request (clinical rationale, benefit-specific notes). Attach any supporting clinical documentation and note management changes or HCPCS updates.

    • Required fields: DRUG NAME; GENERIC/ALTERNATE; PADP indicator; CE/ and SAD** flags (if present); DRUG date; CODE (HCPCS/J-code/C9399); COMMENTS (clinical justification and payer-specific notes).
    • Include HCPCS/J-code mapping and any drug-specific payer comments (e.g., infertility benefit review for certain J3490/J0725/S0122 entries).
    • Supportive documentation: clinical notes, prior treatment history, indication, and any benefit-verification evidence. Note any HCPCS/J-code effective dates or new code mappings in the COMMENTS section.
    Note

    Prime MPS Management & List Updates

    Prime MPS management notes and list update cadence: drugs marked PADP = x will be managed by Prime Therapeutics (Prime MPS) — several drugs are scheduled to be added to PADP effective 03/01/2026 or other effective dates noted. The Medical/Specialty Pharmacy list is updated semiannually (January & July); newly FDA-approved drugs and new/unclassified HCPCS codes require PA based on the unclassified codes listed until a permanent code is assigned.

    • List update cadence: updates added/removed twice yearly (January & July).
    • Newly FDA-approved drugs or drugs with unclassified HCPCS/CPT require PA using unclassified codes (e.g., C9399, J3490, J3590) until a permanent HCPCS is assigned.
    • Management changes affecting routing: entries noting "Effective 03/01/2026, drug will be added to PADP and managed by Prime MPS" — include this in submission comments to route to Prime when applicable.
    Denial Risk

    Benefit Verification & Program Flags (PADP / CE / SAD)

    Benefit verification and program flags: always verify eligibility and benefits before providing services. Many entries include program flags (PADP, CE/, SAD**) that determine the managing entity and whether special program management applies.

    • Verify member coverage/benefit (Eligibility & Benefits) prior to service — PA requirement varies by member product.
    • Interpret flags: PADP = managed by Prime MPS; CE/ and SAD** provide additional routing or special authority notes; include these flags on requests.
    • Denial risk: services (and supportive services) for products that require PA may be denied if authorization is not obtained prior to service.
    Billing Rule

    Coding & Claim Documentation

    Claim coding and coding/documentation notes: include the HCPCS/CPT/Unclassified code(s) referenced, and clearly map the drug to the code used for billing. Note new HCPCS/J-codes and effective dates on the request. For unlisted or unclassified drugs, reference the unclassified code (C9399, J3490, J3590, J7999, etc.) and provide the manufacturer/brand and generic name in the COMMENTS.

    • Required coding on requests: HCPCS or J-code(s) used on the claim; if unclassified code is used (C9399, J3490, J3590, J9999, etc.), include drug brand and generic name.
    • Coding/Documentation note: New HCPCS/J-codes effective 01/01/2026 and other dates are indicated in the list — callers should reference these effective-date comments when completing the PA.
    • Benefit-specific documentation: include notes for specialties (e.g., infertility review required for some J3490/J0725/S0122 entries).
    Step Therapy

    Step Therapy (Not Specified)

    Step therapy: no specific step therapy rules are specified in this extract. Where step therapy applies it will be documented in the drug table or program-specific criteria — include any step-therapy details or prior step history in the submission if applicable.

    • Step therapy rules: not specified in this extract. Providers should include prior medication history if a step-therapy review may be relevant.
    • Operational note: when step therapy is required by the member’s benefit, PA criteria or program-specific guidance will define the required prior agents.

    Policy Background

    This policy governs utilization management for drugs billed to the medical benefit. Many drugs shown on the Medical/Specialty Pharmacy (Rx) Drug List require prior authorization and are subject to medical necessity review before coverage will be approved. Administration and supportive service codes billed with an authorized drug are generally supported by the drug authorization and do not require separate review unless specifically identified. Providers must determine the appropriate submission routing (for example PADP/Prime Therapeutics, CareCentrix for home infusion, PBM vendors, or Availity/Blue Express) based on the specific drug, the member's product, the place of service, and the billing/rendering entity.

    Key Terms & Flags

    PADP definition
    DefinitionPADP = Provider Administered Drug Program — drugs with an 'x' in the PADP column are included in PADP and reviewed by Prime Therapeutics (formerly MRxM/ICORE).
    PurposeIdentifies drugs managed under a pharmacy administrative program for provider-administered drugs requiring PA routing to PADP/Prime.
    List behaviorDrugs added/removed from PADP are reflected in the drug list; some entries include 'Effective 03/01/2026, drug will be added to PADP and managed by Prime MPS.'
    Voluntary Predetermination (Advanced Benefit Determination)
    DefinitionVoluntary Predetermination (Advanced Benefit Determination) — an available option for select services to determine coverage in advance.
    Where to requestRefer to the Utilization Management section (Voluntary Predetermination for Select Services) per product; FEP examples reference Advanced Benefit Determination for select services.
    Use caseHelps verify member benefits and medical necessity prior to service for applicable products/services.
    PADP / CE/ / SAD** annotation fields used in the drug list
    Annotation fieldsPADP / CE/ / SAD** — columns present on the drug list used to indicate program placement (PADP), coverage/clinical evaluation flags (CE/), and SAD** status/dates.
    Displayed dataEach drug entry shows DRUG NAME, GENERIC/ALTERNATE NAME, PADP, CE/, SAD**, DRUG (date), CODE and COMMENTS which should be referenced when submitting PA requests.
    InterpretationAn 'x' in PADP indicates review by PADP/Prime; CE/ marks items for clinical evaluation; SAD** entries include status dates or special annotation.
    Document-specific program flags (PADP / CE/ / SAD**)
    Program flags presentThe document includes program flags (PADP, CE/, SAD**) next to drug entries to indicate special processing or program management.
    ExamplesEntries show PADP = x for many biologics/biosimilars (e.g., trastuzumab biosimilars, pegfilgrastim biosimilars); comments note future PADP additions effective 03/01/2026 for certain drugs.
    Provider actionWhen a flag is present, include the flag and listed code in PA submission and route to the program/vendor indicated (Prime MPS/CCX/etc.).
    PADP flag description
    PADP flag meaning'PADP' column indicates products assigned to the Provider Administered Drug Program (drugs with 'x' are managed by Prime Therapeutics/ PADP).
    Effect on routingPA requests for PADP‑marked drugs should be submitted to Prime Therapeutics Management (gatewaypa.com/provider tab) or as directed in the Provider Manual.
    Effective changesSome PADP additions are effective 03/01/2026 — verify routing and management vendor for the service date shown on the drug entry.
    CE/ flag description
    CE/ flag meaning'CE/' indicates items requiring clinical evaluation or are subject to coverage/designation review as noted in the drug list.
    UsageCE/ is displayed per drug entry alongside PADP and SAD** to guide authorization processing and may indicate additional clinical review requirements.
    Submission noteInclude CE/ designation when submitting PA and provide supporting clinical documentation as requested.

    Step Therapy / Management Notes

    NoteEffective date / impact
    Several drug entries include a comment that they will be added to the Provider Administered Drug Program (PADP) and managed by Prime MPS.Effective 03/01/2026 — may change prior authorization routing and program management (providers should verify submission destination and program requirements after this date).
    Examples shown in the list: NULIBRY (J1809) and multiple other entries indicate 'Effective 03/01/2026, drug will be added to PADP and managed by Prime MPS.'Effective 03/01/2026 — these specific drugs will be subject to PADP/Prime MPS management per the document comments; prior authorization requirements or routing may change accordingly.
    Additional J-code entries (e.g., J2468 / palonosetron-related entry) include the same PADP/Prime MPS comment in this segment.Effective 03/01/2026 — plan and vendor management changes noted; providers must confirm where to submit PA requests once management transfers occur.

    Place-of-Service & Submission Routing

    Billing Rule

    Route PA by place of service (home, outpatient, retail/infusion)

    Submission routing depends on place of service: home infusion, outpatient facility, or retail/infusion pharmacy — identify the place of service to determine whether to route to CareCentrix, PADP/Prime, PBM, or Availity/Blue Express.

    • Home infusion/AIS participating providers: CareCentrix coordination.
    • PADP-managed drugs or PADP-listed providers: Prime Therapeutics gateway.
    Billing Rule

    Vendor-specific routing for physician/outpatient-billed drugs

    Certain drugs billed by Florida physicians or outpatient facilities are routed to specific vendors; CareCentrix coordinates reviews for home health/home infusion/AIS participating providers per the policy.

    • CareCentrix Phone: 877-561-9910; Fax: 877-627-6688 for participating home infusion/AIS providers.
    • FEP and certain Part D/MedAdv routing to Prime Therapeutics or PBMs as noted.
    Billing Rule

    Use PADP/CE flags to determine outpatient/infusion routing

    PADP and CE flags on entries often indicate outpatient applicability and specialty pharmacy/infusion center management; when these flags are present, route PA and billing consistent with outpatient/infusion site requirements.

    • Entries show PADP or CE flags and comments such as 'Effective 03/01/2026, drug will be added to PADP and managed by Prime MPS' for outpatient/administered products.
    Note

    HCPCS/J-code drugs imply site-specific routing (infusion/clinic/home)

    Drugs listed are HCPCS/J-code administered medical-benefit products; site-specific settings (infusion/clinic/home) are implied by HCPCS billing and should be considered when routing PA and billing.

    • HCPCS/J-code administration implies medical-benefit setting such as infusion center or clinic; follow site-of-care routing guidance in the policy.
    Policy Summary
    PayerFlorida Blue
    PolicyMedical/Specialty Pharmacy (Rx) Drug Prior Authorization Requirements
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization referencing the listed drug, member product type and place of service before billing to avoid claim denial.
    SourceLink
    On This Page
    Coverage & Authorization ConditionsHCPCS / J-Code / CPT ListingsWhat Providers Must DoPolicy BackgroundKey Terms & FlagsStep Therapy / Management NotesPlace-of-Service & Submission Routing